Augmentation of exposure therapy with D-cycloserine for social anxiety disorder

Archives of General Psychiatry

Volumn 63, Issue 3, 2006, Pages 298-304

  Hofmann, Stefan G ^a   Meuret, Alicia E ^a   Smits, Jasper A J ^c   Simon, Naomi M ^b   Pollack, Mark H ^b   Eisenmenger, Katherine ^a   Shiekh, Michael ^c   Otto, Michael W ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMOTIONAL DISORDER; EUPHORIA; FEMALE; FOLLOW UP; GROUP THERAPY; HUMAN; MALE; NIGHTMARE; PSYCHOMETRY; PSYCHOTHERAPY; PUBLIC SPEAKING; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOCIAL PHOBIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; COMBINED MODALITY THERAPY; CYCLOSERINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEAR; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; PHOBIC DISORDERS; PLACEBOS; PSYCHOTHERAPY, GROUP; RECEPTORS, N-METHYL-D-ASPARTATE; SPEECH;

EID: 33644755641     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.3.298     Document Type: Article

References (57)

1. Kessler RC, McGonagle KA, Shanyang Z, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Davidson JRT, Foa EB, Huppert JD, Keefe F, Franklin M, Compton J, Zhao N, Connor K, Lynch TR, Kishore G. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61:1005-1013.
3. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiatry. 1985;42:729-736.
4. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiological sample. Arch Gen Psychiatry. 1992;49:282-288.
5. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon B, Gitow A, Street L, DelBene D, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322-331.
6. Stein MB, Walker JR, Forde DR. Public speaking fears in a community sample: prevalence, impact on functioning, and diagnostic classification. Arch Gen Psychiatry. 1996;53:169-174.
7. Stein MB, Torgrud LJ, Walker J. Social phobia symptoms, subtypes, and severity: findings from a community survey. Arch Gen Psychiatry. 2000;57:1046-1052.
8. Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am J Psychiatry. 2000;157:1606-1613.
9. Mannuzza S, Schneier FR, Chapman TF, Liebowitz MR, Klein DF, Fyer AJ. Generalized social phobia: reliability and validity. Arch Gen Psychiatry. 1995;52:230-237.
10. Pollard CA, Henderson JG. Four types of social phobia in a community sample. J Nerv Ment Dis. 1988;176:440-445.
11. Clark DM, Ehlers A, McManus F, Hackman A, Fennell M, Campbell H, Flower T, Davenport C, Louis B. Cognitive therapy vs fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003;71:1058-1067.
12. Gould RA, Buckminster S, Pollack MH, Otto MW, Yap L. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Pract. 1997;4:291-306.
13. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 1998;55:1133-1141.
14. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708-713.
15. Feske U, Chambless DL. Cognitive behavioral vs exposure only treatment for social phobia: a meta-analysis. Behav Ther. 1995;26:695-720.
16. Taylor S. Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry. 1996;27:1-9.
17. Otto MW, Pollack MH, Gould RA, Worthington JJ III, McArdle ET, Rosenbaum JF. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000;14:345-358.
18. Foa EB, Franklin ME, Perry KJ, Herbert JD. Cognitive biases in generalized social phobia. J Abnorm Psychol. 1996;105:433-439.
19. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12:72-86.
20. Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci. 1992;12:854-863.
21. Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci. 2001;21:9009-9017.
22. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136-1144.
23. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology. 1996;46:420-424.
24. Myers KM, Davis M. Behavioral and neural analysis of extinction: a review. Neuron. 2002;36:567-584.
25. Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of conditioned fear as assessed by freezing in rats. Behav Neurosci. 2003;117:341-349.
26. Davis M, Walker DL, Myers KM. Role of the amygdala in fear extinction measured with potentiated startle. Ann N Y Acad Sci. 2003;985:218-232.
27. Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22:2343-2351.
28. Boje KM, Wong G, Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res. 1993;603:207-214.
29. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257:7-12.
30. Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005;83:224-231.
31. Hofmann SG. Cognitive mediation of treatment change in social phobia. J Consult Clin Psychol. 2004;72:393-399.
32. Newman MG, Hofmann SG, Trabert W, Roth WT, Taylor CB. Does behavioral treatment of social phobia lead to cognitive changes? Behav Ther. 1994;25:503-517.
33. DiNardo PA, Brown TA, Barlow DH. Anxiety Disorders Interview Schedule for DSM-IV: Lifetime Version (ADIS-IV-L). New York, NY: Graywind Publications Inc; 1994.
34. First MB, Spitzer RL, Gibbon M, Williams JBW.Structured Clinical Interview for DSM-IV (Axis I Disorders). Arlington, Va: American Psychiatric Publishing Inc; 1997.
35. Brown TA, Di Nardo PA, Lehman CL, Campbell LA. Reliability of DSM-IV anxiety and mood disorders: implications for the classification of emotional disorders. J Abnorm Psychol. 2001;110:49-58.
36. Turner SM, Beidel DC, Dancu CV, Stanley MA. An empirically derived inventory to measure social fears and anxiety: the Social Phobia and Anxiety Inventory. Psychol Assess. 1989;1:35-40.
37. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141-173.
38. Guy W. The Clinical Global Impressions Scale. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: National Institute of Mental Health; 1976:217-222.
39. Beidel DC, Borden JW, Turner SM, Jacob RG. The Social Phobia and Anxiety Inventory: concurrent validity with a clinic sample. Behav Res Ther. 1989;27:573-576.
40. Baker SL, Heinrichs N, Kim HJ, Hofmann SG. The Liebowitz Social Anxiety Scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther. 2002;40:701-715.
41. Deviliya GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31:73-86.
42. Physicians' Desk Reference. 58th ed. Montvale, NJ: Medical Economics Co; 2004.
43. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry. 2000;47:450-462.
44. Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol. 1995;8:226-230.
45. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN. D-cycloserine treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord. 1994;8:198-205.
46. van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40:1298-1300.
47. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1983.
48. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
49. Rosnow RL, Rosenthal R. Computing contrasts, effect sizes, and counternulls on other people's published data: general procedures for research consumers. Psychol Methods. 1996;1:331-340.
50. Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry. 2005;57:841-847.
51. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63-69.
52. Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(2):CD003153.
53. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158:1367-1377.
54. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56:21-27.
55. Flood JF, Morley JE, Lanthorn TH. Effect on memory processing by D-cycloserine, an agonist for the NMDA/glycine receptor. Eur J Pharmacol. 1992;221:249-254.
56. Land C, Riccio DC. d-Cycloserine: effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem. 1999;72:158-168.
57. Matsuoka N, Aigner TG. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys. J Pharmacol Exp Ther. 1996;278:891-897.